Experimental drug fails to show slowing of dementia in blow to Alzheimer's research
An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
While the trials were successful in showing a slight rate of decline, neither of them were described by Roche as being "statistically significant."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and head of global product development. "We are profoundly grateful to the study participants, their care partners, and study sites for their contributions to this research."
The faults of the studies now leave a trio of Roche's competitors, Biogen, Eisai, and Eli Lilly as the leaders in the medical community's effort to get an Alzheimer's treatment on the market.
The results saw economic ramifications as well, and Reuters reported that financial services firm Credit Suisse called the studies an "unequivocal" failure. Shares of Roche fell to their lowest in seven weeks, Reuters noted, with shares of Biogen and Eli Lilly rising 3.8 percent and 2.3 percent, respectively.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Justin Klawans has worked as a staff writer at The Week since 2022. He began his career covering local news before joining Newsweek as a breaking news reporter, where he wrote about politics, national and global affairs, business, crime, sports, film, television and other Hollywood news. Justin has also freelanced for outlets including Collider and United Press International.
-
'Make legal immigration a more plausible option'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
LA-to-Las Vegas high-speed rail line breaks ground
Speed Read The railway will be ready as soon as 2028
By Peter Weber, The Week US Published
-
Israel's military intelligence chief resigns
Speed Read Maj. Gen. Aharon Haliva is the first leader to quit for failing to prevent the Hamas attack in October
By Justin Klawans, The Week US Published
-
Lead poisoning remains a threat
The Explainer The toxin is built into our lives
By Devika Rao, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
The alarming rise of cancer in young people
Under the radar Cancer rates are rising, and the cause is not clear
By Devika Rao, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Narcan is becoming harder to find at drugstores across America
Under the Radar The drug, also known as naloxone, reverses the effects of an opioid overdose
By Justin Klawans, The Week US Published
-
The lows of an unregulated high: Teens are using marijuana alternative delta-8
In the Spotlight More than 1 in 10 high school seniors have reported using the substance, which contains concentrated THC
By Justin Klawans, The Week US Published
-
Our microbiome is social like us
The Explainer Microbes can be friendly too
By Devika Rao, The Week US Published